Related Experiment Videos
Four year double-blind controlled study of levamisole in multiple sclerosis
A R Massaro1, R P Cioffi, A Laudisio
1Istituto di Neurologia, Università del Sacro Cuore, Roma.
Italian Journal of Neurological Sciences
|December 1, 1990
Summary
Levamisole treatment significantly reduced relapses in multiple sclerosis (MS) patients over four years. This study suggests levamisole is effective in managing MS exacerbations, though individual responses may vary.
Area of Science:
- Neurology
- Immunology
- Clinical Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Managing relapses is a key challenge in MS treatment.
- Understanding immunomodulatory effects can inform therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of levamisole in reducing exacerbations in patients with definite multiple sclerosis.
- To assess the long-term impact of levamisole treatment on MS disease activity.
Main Methods:
- A four-year, double-blind, placebo-controlled study involving 41 patients with definite MS in the stationary phase.
- Patients were randomized to receive either levamisole (150 or 200 mg weekly) or a placebo.
- Treatment cessation and classification as a 'negative' outcome occurred upon clear exacerbation.
Main Results:
- Levamisole treatment resulted in significantly fewer relapses compared to placebo.
- 8 out of 22 levamisole-treated patients experienced exacerbations, versus 14 out of 19 placebo-treated patients.
- The observed difference in relapse rates between the levamisole and placebo groups was statistically significant.
Conclusions:
- Levamisole significantly reduces the frequency of acute relapses in multiple sclerosis patients over a four-year treatment period.
- The study indicates levamisole's potential as an effective therapy for managing MS relapses.
- Variability in patient response suggests potential underlying differences in MS immunopathology.